Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15832432 | 0.73 | TSHR (0.46) | SLC6A3LMNATSHREGFRMAP3K14 | |
| SCHEMBL14457868 | 0.71 | EGFR (0.45) | AHRSLC6A3HPGDNPSR1EGFR | |
| SCHEMBL24363905 | 0.70 | AHR (0.41) | AHRSLC6A3NPC1LMNAHPGD | |
| SCHEMBL17207479 | 0.69 | HTR1A (0.34) | NPC1 | |
| SCHEMBL22040181 | 0.66 | NISCH (0.41) | PGR | |
| SCHEMBL22039759 | 0.66 | NISCH (0.41) | PGR | |
| SCHEMBL19873024 | 0.65 | MAOB (0.54) | AHRNPC1LMNARAB9AMAPK10 | |
| SCHEMBL1977761 | 0.62 | CHRNB4 (0.54) | AHRSLC6A3HPGDNPSR1PGR | |
| SCHEMBL29769221 | 0.61 | AHR (1.00) | AHRNPC1TSHRRAB9A | |
| SCHEMBL137915 | 0.61 | AHR (1.00) | AHRNPC1TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150307496-A1 | NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-a]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307496-A1 | NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-a]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | AHR 1978/4885SLC6A3 4775/4885NPC1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.